Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Goodwill for the quarter ending September 30, 2024: USD 21.21 M

Evolus, Inc. Goodwill is USD 21.21 M for the quarter ending September 30, 2024, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Evolus, Inc. Goodwill for the quarter ending September 30, 2023 was USD 21.21 M, a 0.00% change year over year.
Evolus, Inc. Goodwill for the quarter ending September 30, 2022 was USD 21.21 M, a 0.00% change year over year.
Evolus, Inc. Goodwill for the quarter ending September 30, 2021 was USD 21.21 M, a 0.00% change year over year.
Evolus, Inc. Goodwill for the quarter ending September 30, 2020 was USD 21.21 M, a 0.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Dental Care Eyewear Personal Care

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years